Composition of matter

Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

Retrieved on: 
Wednesday, February 7, 2024
Patent, Family, MAR, Composition, MYIG, OTC, MDMA, Mental health, Composition of matter, Fine chemical

Mydecine received its second Notice of Allowance from the USPTO, on one of its novel compounds for Composition of Matter that is currently under development.

Key Points: 
  • Mydecine received its second Notice of Allowance from the USPTO, on one of its novel compounds for Composition of Matter that is currently under development.
  • The molecule is from the MYCO-005 family of psilocin analogs, and it is the second in this family to receive a Notice of Allowance.
  • Additional molecules in this family are still under review at the USPTO.
  • Mydecine received Notice of Allowance from the USPTO, on one of its novel compounds under development.

Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas

Retrieved on: 
Thursday, December 28, 2023
Annex, Risk, FDA, Brussels Stock Exchange, CDO, Convertible, USD, CSO, Communication, Geographic atrophy, Drug development, CFO, Executive Committee, Bankruptcy, AMD, Disease, Rothschild Bank, Cayman, Debt, EUR, Capital, Therapy, Paratriathlon, Running, Working capital, Person, New Board, Injection, Composition, Composition of matter, Patient, TotalEnergies, Medicine, Partnership, Section 1, Doctor of Philosophy, IVT, Prospectus, LOI, Negotiation, Retina, Security (finance)

Given this market potential, vast amounts of time and capital that have been invested to find an effective treatment for GA.

Key Points: 
  • Given this market potential, vast amounts of time and capital that have been invested to find an effective treatment for GA.
  • Earlier this year the FDA approved the first medicine for the treatment of GA, SYFOVRE®1 (pegcetacoplan injection) from Apellis.
  • In August of this year, a second product was approved for GA, IZERVAY™2(avacincaptad pegol intravitreal solution) from Iveric Bio, an Astellas company, with a similar profile to SYFOVE.
  • In the event the total Working Capital costs would amount to the total remaining amount under the Atlas funding program, i.e.

NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

Retrieved on: 
Monday, December 18, 2023
CNS, World Health Organization, Composition, Urinary tract infection, Dark Enlightenment, Urine, QIDP, IND, GWU, Baylor University, DCS, Nick Cuti, Learning, Hope, NMDA, Sepsis, Patient, FDA, UTI, Friends, George Washington University, Tropical medicine, Bacteria, University, Composition of matter, MD, Accenture, Engineering, Death, Failure, Microbiology, Hospital, GSK plc, Pharmaceutical industry, Urology, Immunology

"Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have become increasingly resistant to commonly used antibiotics.

Key Points: 
  • "Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have become increasingly resistant to commonly used antibiotics.
  • New treatment options are urgently needed" stated Jonathan Javitt, MD MPH, Founder and Chief Scientist of NRx Pharmaceuticals.
  • "The D-cycloserine (DCS) component of NRX-101 is well known as an antibiotic and is excreted unmetabolized in the urine.
  • The company awaits the FDA's response to its request for Qualified Infectious Disease Product (QIDP) designation, expected next month.

SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent

Retrieved on: 
Thursday, November 9, 2023
FRSC, Psoriasis, MD–PhD, Patent, Composition of matter, SFA, TB, Cytokine, FRCPC, University, Research, Psoriasis Area and Severity Index, Conditional sentence, IGA, Disease, Cancer, Autoimmune disease, OC, Infection, Safety, Therapy, Patient, PASI, Immunosuppression, Toxic leukoencephalopathy, Pharmaceutical industry

Additional participants in this raise were the Ben Franklin Technology Partners of Pennsylvania, Savantus Ventures and Asymmetry Ventures.

Key Points: 
  • Additional participants in this raise were the Ben Franklin Technology Partners of Pennsylvania, Savantus Ventures and Asymmetry Ventures.
  • SFA-002 is an oral pill that simultaneously acts on multiple therapeutic pathways, unlike other drugs on the market which target a single channel.
  • SFA Therapeutics is also pleased to announce that North South Ventures Managing Partner, Dr. David Naylor, MD/PhD, OC, FRCPC, FRSC, has joined SFA Therapeutics’ Board of Directors.
  • Psoriasis is an incurable chronic disease that affects 125 million people worldwide, with the global psoriasis treatment market size projected to grow at a CAGR of 9.2%.

PharmAla Files Patent for Novel MDXX Molecule PharmAla-1

Retrieved on: 
Monday, July 31, 2023
ABA, University, Autumn, Ontario Centre of Forensic Sciences, Partnership, CSE, Spectrum, Autism spectrum, Medicine, University of Arkansas for Medical Sciences, MDXX, Hope, Innovation, Research, Composition of matter, IP, Computational chemistry, CNS, Drug design, Central nervous system, MDMA, Patent, ASD, NCE, ALA, Psychedelic drug, OTC, Drug discovery, Psychiatry, Social anxiety, Safety, Pharmaceutical industry, Pharmacology

PharmAla’s novel drug development pipeline has been advancing rapidly in 2023, with PharmAla’s ALA family moving rapidly into clinical development.

Key Points: 
  • PharmAla’s novel drug development pipeline has been advancing rapidly in 2023, with PharmAla’s ALA family moving rapidly into clinical development.
  • The Composition of Matter patent on the Novel Chemical Entity (NCE) PharmAla-1 will further strengthen the company’s position as a leading developer of Central Nervous System (CNS) pharmaceutical treatments.
  • PharmAla-1 is the first molecule of PharmAla’s extensive computational drug development pipeline, which PharmAla is announcing to the market in detail; PharmAla’s ALA and ABA patent families were developed via traditional drug discovery.
  • PharmAla is also excited to announce the acceptance of its review article titled "Balancing therapeutic efficacy and safety of MDMA and novel MDXX analogues as novel treatments for autism spectrum disorder" for publication in Psychedelic Medicine.

Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

Retrieved on: 
Monday, May 22, 2023
Infarction, MI, Myocardial infarction, Heart failure, Disability, HF, Splenic infarction, Research, Composition of matter, Cytosol, PLB, Cardioprotection, Composition, Patient, PKA, NCE, Poster, PPI, Heart rate, SERCA2, Inst, Death, IND, Pharmaceutical industry

OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023, the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.

Key Points: 
  • OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023 , the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.
  • 13-M is a small NCE shown to have these important protein to protein interaction (PPI) characteristics with the capacity to modulate the SERCA2 Ca2+ pump.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • Without treatment, 30% of MI patients will go on to develop heart failure.

Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

Retrieved on: 
Monday, May 22, 2023
Infarction, MI, Myocardial infarction, Heart failure, Disability, HF, Splenic infarction, Research, Composition of matter, Cytosol, PLB, Cardioprotection, Composition, Patient, PKA, NCE, Poster, PPI, Heart rate, SERCA2, Inst, Death, IND, Pharmaceutical industry

OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023, the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.

Key Points: 
  • OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023 , the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.
  • 13-M is a small NCE shown to have these important protein to protein interaction (PPI) characteristics with the capacity to modulate the SERCA2 Ca2+ pump.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • Without treatment, 30% of MI patients will go on to develop heart failure.

EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio

Retrieved on: 
Thursday, March 2, 2023
Inflammation, HEPA, European Patent Convention, Doctor of Philosophy, Doctor of Pharmacy, Cancer, Thrombosis, Fatty liver disease, Conditional sentence, Composition of matter, European Patent Office, Artificial intelligence, Fibrosis, Pharmaceutical industry

EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that the European Patent Office (“EPO”) has granted European Patent No. EP 3886813, covering the innovative formulation of Hepion’s lead cyclophilin inhibitor, rencofilstat.

Key Points: 
  • The newly granted European patent also significantly extends the time period of Hepion’s patent exclusivity for rencofilstat.
  • The Company’s original composition-of-matter patent estate, comprising 52 patents issued in every major market throughout the world, are expected to provide exclusivity to 2036.
  • The newly granted rights, which will encompass 38 European countries, are expected to extend the drug candidate’s patent life by approximately eight years, to 2044.
  • To that end, our expanding intellectual property estate, including this new European patent, should ensure that rencofilstat has long-term market exclusivity.”

First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028

Retrieved on: 
Wednesday, February 15, 2023
Physician, Lysergic acid diethylamide, Human, N, Safety, Patient, Chief scientific officer, Depression, LSD, IM, Psilocybin, DMT, IV, Comparison, Learning, Composition of matter, Pharmacokinetics, Composition, Pharmaceutical industry

LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today confirms that the first subject has been dosed in a Phase I study evaluating SPL028, its deuterated N, N-dimethyltryptamine (“DMT”) candidate, with supportive therapy in healthy volunteers. This is the first-in-human trial investigating the profile of SPL028, the Company’s proprietary molecule with Composition of Matter protection.

Key Points: 
  • This is the first-in-human trial investigating the profile of SPL028, the Company’s proprietary molecule with Composition of Matter protection.
  • Small Pharma’s preclinical studies suggest that SPL028 offers a similar safety and pharmacological profile to its lead candidate SPL026, or DMT, while being differentiated by its pharmacokinetics.
  • Through the SPL028 clinical program, Small Pharma is exploring whether an extended duration could offer a treatment tailored for other mental health conditions in addition to depression.
  • The Phase I study is a randomized, blinded, placebo-controlled, dose-escalating study being conducted at MAC Clinical Research in Manchester, England.

Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

Retrieved on: 
Wednesday, February 1, 2023
Composition, Composition of matter, Small, Intellectual property, United States Patent and Trademark Office, Patent, Tryptamine, GMP, Research, Pharmaceutical industry

LONDON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP”) portfolio.

Key Points: 
  • LONDON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP”) portfolio.
  • Small Pharma has also received an Issue Notification from the USPTO that patent no.
  • Following their issuance, the two new U.S. patents will bring the Company’s total number of granted patents in its psychedelic and non-psychedelic portfolio to 16, with over 90 pending applications.
  • Small Pharma has developed a multi-layered patent strategy targeting key areas of protection across its research and development pipeline.